Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Amifampridine Phosphate Patent Expiration

Amifampridine Phosphate is Used for treating Lambert-Eaton Myasthenic Syndrome. It was first introduced by Catalyst Pharmaceuticals Inc in its drug Firdapse on Nov 28, 2018.


Amifampridine Phosphate Patents

Given below is the list of patents protecting Amifampridine Phosphate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Firdapse US10626088 Determining degradation of 3,4-diaminopyridine Feb 25, 2037 Catalyst Pharms
Firdapse US10793893 Methods of administering 3,4-diaminopyridine May 26, 2034 Catalyst Pharms
Firdapse US11060128 Methods of administering 3,4-diaminopyridine Jun 29, 2032 Catalyst Pharms
Firdapse US11268128 Methods of administering 3,4-diaminopyridine Jun 29, 2032 Catalyst Pharms
Firdapse US11274331 Methods of administering 3,4-diaminopyridine Jun 29, 2032 Catalyst Pharms
Firdapse US11274332 Methods of administering 3,4-diaminopyridine Jun 29, 2032 Catalyst Pharms


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳